Personalized Neoantigen Peptide Vaccine
Solid Tumor, Adult
Seqker Biosciences, Inc.vaccinePhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 65/ 100
Competitive context
229 Active assets in the Solid Tumor, Adult cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Verastem, Inc. | Phase 2 | B |
Nivolumab ImmuneSensor Therapeutics Inc. | Phase 1/2 | B |
Atezolizumab KaliVir Immunotherapeutics | Phase 2 | B |
FLUOROURACILUM TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 2 | B |
Cyclophosphamide TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Personalized Neoantigen Peptide Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →